Setting the tone for a wave of suits looming on the horizon, the U.S. Supreme Court this week deliberated on some of the issues related to retirement plan investors who have tried to sue for lower-than-promised returns and alleged market manipulations.

On Monday, justices addressed the merits of a class-action suit launched by the multi-billion-dollar Connecticut public employee retirement system against Amgen Inc., a Thousand Oaks, Calif.-based biotechnology firm.

The pension fund and other investors have taken aim at Amgen, claiming that the company witheld information regarding the safety of two of its new medications, and that once the information was revealed, stock prices plummeted.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.